공시 • Jun 19
Regentis Biomaterials Ltd. announced that it expects to receive $6.5 million in funding Regentis Biomaterials Ltd. entered into definitive securities purchase agreements with certain accredited and institutional investors for issuance of 1,844,543 common shares at a price of $3.50 per share for gross proceeds of $6,455,900.50; and 12,600 pre-funded warrants at a price of $3.4999 per pre-funded warrant for gross proceeds of $44,098.74; for aggregate gross proceeds of $6,499,999.24 on June 17, 2026. The company will also issue ordinary warrants to purchase up to 1,857,143 ordinary shares. The pre-funded warrants have an exercise price of $0.0001 per ordinary share, are immediately exercisable upon issuance and will not expire until exercised in full. The ordinary warrants have an exercise price of $4.20 per ordinary share, are immediately exercisable upon issuance and will expire on the five-year anniversary from the date of issuance. The offering is expected to close on or about June 23, 2026. The ordinary shares, the warrants and the ordinary shares issuable upon exercise of the warrants were offered and sold pursuant to an exemption from the registration requirements of the securities act of 1933, as amended, under Section 4(a)(2) of the Securities Act and Rule 506(c) of Regulation D promulgated thereunder. 공시 • Jun 15
Regentis Biomaterials Ltd. has withdrawn its Follow-on Equity Offering in the amount of $10.000002 million. Regentis Biomaterials Ltd. has withdrawn its Follow-on Equity Offering in the amount of $10.000002 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 3,333,334
Price\Range: $3
Discount Per Security: $0.21 공시 • Jun 09
Regentis Biomaterials Ltd. Commences European Surgeon Training for GelrinC in Knee Cartilage Repair as Commercial Launch Preparations Accelerate Regentis Biomaterials Ltd. announced that in the third quarter of 2026, the Company plans to commence its European surgeon training activities, as it advances preparations for the commercial rollout of GelrinC in Europe, where it has CE Mark approval. The hands-on training program is designed to train orthopedic surgeons in the use of GelrinC, providing practical experience with the implantation procedure and supporting physician readiness ahead of market launch. The first training activities are expected to take place in Milan, Italy, at Humanitas Research Hospital. Additional sessions are planned in other European markets. GelrinC is a cell-free implant for the treatment of knee cartilage lesions. The procedure utilizes a ready-to-use implant and a straightforward single-step implantation process, which takes approximately 10 minutes, and fits into the surgeon's workflow. Regentis is establishing a network of European Centers of Excellence designed to support surgeon education, clinical guidance, and knowledge sharing around cartilage repair and the use of GelrinC. These centers are intended to serve as clinical hubs where experienced orthopedic surgeons will help train and support other physicians across Europe as the technology is introduced into clinical practice. Regentis is targeting an estimated $3 billion U.S. market of 470,000 annual knee cartilage repair cases, where no approved off-the-shelf regenerative solution currently exists. Clinical data have shown approximately 100% greater pain improvement versus standard of care microfracture, alongside MRI-confirmed regeneration of near-native cartilage and durable multi-year outcomes. GelrinC has CE Mark approval in the European Union and is now being evaluated in a pivotal U.S. Food and Drug Administration study, which has completed over 50% enrollment. 공시 • May 29
Regentis Biomaterials Ltd., Annual General Meeting, Jul 02, 2026 Regentis Biomaterials Ltd., Annual General Meeting, Jul 02, 2026. Location: apm house, 18 raoul wallenberg st., building d, 6th floor, ramat hachayal, tel aviv, Israel New Risk • May 19
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: US$10.00m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 9.4% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (US$10.00m market cap). 공시 • May 03
Regentis Biomaterials Ltd. has filed a Follow-on Equity Offering in the amount of $10.000002 million. Regentis Biomaterials Ltd. has filed a Follow-on Equity Offering in the amount of $10.000002 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 3,333,334
Price\Range: $3
Discount Per Security: $0.21 
